Suppr超能文献

长期服用抗抑郁药物对大鼠海马体中增强电诱发[3H]去甲肾上腺素释放的5-HT3受体的影响。

Effect of long-term administration of antidepressant drugs on the 5-HT3 receptors that enhance the electrically evoked release of [3H]noradrenaline in the rat hippocampus.

作者信息

Mongeau R, De Montigny C, Blier P

机构信息

Department of Psychiatry, McGill University, Montréal, Québec, Canada.

出版信息

Eur J Pharmacol. 1994 Dec 12;271(1):121-9. doi: 10.1016/0014-2999(94)90272-0.

Abstract

The present study investigated the effects of various classes of antidepressant drugs (10 mg/kg per day, s.c. during 21 days) on the electrically evoked release of [3H]noradrenaline and on its modulation by the 5-HT3 receptor agonist 2-methyl-5-hydroxy-tryptamine (2-methyl-5-HT) using preloaded rat hippocampal slices. Treatments with either fluoxetine, a selective serotonin (5-HT) reuptake inhibitor, or moclobemide, a reversible type A monoamine oxidase inhibitor, increased the evoked release of [3H]noradrenaline. These two antidepressant treatments did not change, however, the magnitude of the enhancing effect of 2-methyl-5-HT on the electrically evoked release of [3H]noradrenaline. Desipramine produced a much larger increase of the electrically evoked release of [3H]noradrenaline than fluoxetine or moclobemide, and desensitized the 5-HT3 receptors that modulate this release. Trimipramine, which like desipramine has a tricyclic structure but does not block the reuptake of noradrenaline or that of 5-HT, did not increase the evoked release of [3H]noradrenaline and did not desensitize the 5-HT3 receptors that enhance the release of [3H]noradrenaline. Maprotiline, a selective noradrenaline reuptake inhibitor, did not produce the same changes as desipramine, but maprotiline inhibited noradrenaline reuptake to a lesser extent (50%) than desipramine (80%). These results suggest that the high potency noradrenaline reuptake blocker desipramine desensitizes 5-HT3 receptors modulating [3H]noradrenaline release, but that this effect is not common to all antidepressant drugs.

摘要

本研究使用预先装载的大鼠海马切片,研究了各类抗抑郁药物(每天10毫克/千克,皮下注射,持续21天)对电诱发的[3H]去甲肾上腺素释放的影响,以及5-HT3受体激动剂2-甲基-5-羟基色胺(2-甲基-5-HT)对其的调节作用。用选择性5-羟色胺(5-HT)再摄取抑制剂氟西汀或可逆性A型单胺氧化酶抑制剂吗氯贝胺进行治疗,可增加[3H]去甲肾上腺素的诱发释放。然而,这两种抗抑郁治疗并未改变2-甲基-5-HT对电诱发的[3H]去甲肾上腺素释放的增强作用的幅度。地昔帕明比氟西汀或吗氯贝胺产生的电诱发[3H]去甲肾上腺素释放增加幅度大得多,并使调节这种释放的5-HT3受体脱敏。与地昔帕明一样具有三环结构但不阻断去甲肾上腺素或5-HT再摄取的曲米帕明,并未增加[3H]去甲肾上腺素的诱发释放,也未使增强[3H]去甲肾上腺素释放的5-HT3受体脱敏。选择性去甲肾上腺素再摄取抑制剂马普替林产生的变化与地昔帕明不同,但马普替林抑制去甲肾上腺素再摄取的程度(50%)比地昔帕明(80%)小。这些结果表明,高效能去甲肾上腺素再摄取阻滞剂地昔帕明使调节[3H]去甲肾上腺素释放的5-HT3受体脱敏,但这种作用并非所有抗抑郁药物都具有。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验